Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option. The aim of our study was to evaluate outcomes and prognostic parameters in patients with intrahepatic...
Alternative Titles
Full title
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9cbd149114394cddba536f6d8eecaa65
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9cbd149114394cddba536f6d8eecaa65
Other Identifiers
ISSN
2075-1729
E-ISSN
2075-1729
DOI
10.3390/life13112170
